Results 11 to 20 of about 39,017 (214)

Abstract 078: Managing Clopidogrel Resistance in Neurointervention: Surveying Current Approaches

Stroke: Vascular and Interventional Neurology, 2023
Introduction Due to the variability in patient responses to clopidogrel, adjusting antiplatelet regimen based on platelet function testing has become a widespread practice to reduce thromboembolic complications in neurointervention.
Hyun Woo Kim, Ivo Bach, Juan Carlos Martinez‐Gutierrez, Adam Dmytriw, Hussein Zeineddine, Salvatore D'Amato, Sunil Sheth   +6 more
doaj   +2 more sources

Managing Clopidogrel Resistance in Neurointervention: Surveying Current Approaches [PDF]

Stroke: Vascular and Interventional Neurology
Background Because of the variability in patient responses to clopidogrel and to reduce the risk of thromboembolic complications, adjusting the antiplatelet regimen based on platelet function testing has become a widespread practice in neurointervention.
Hyun Woo Kim, Ivo Bach, Juan Carlos Martinez Gutierrez, Adam A. Dmytriw, Salvatore D'Amato, Hussein A. Zeineddine, Albert J. Yoo, Sunil A. Sheth   +7 more
doaj   +2 more sources

Cyp2C19*2 Polymorphism Related to Clopidogrel Resistance in Patients With Coronary Heart Disease, Especially in the Asian Population: A Systematic Review and Meta-Analysis [PDF]

Frontiers in Genetics, 2020
In recent years, the relationship between Cyp2C19*2 gene polymorphism and clopidogrel resistance reflected by platelet function assay has been studied extensively, but there is no clear conclusion yet.
Ying Sun, Qing Lu, Xuefei Tao, Biao Cheng, Guoxing Yang   +4 more
doaj   +2 more sources

Clopidogrel resistance and genetic factors

Türk Kardiyoloji Derneği Arşivi, 2013
Dual antiplatelet therapy combining aspirin and clopidogrel is the standart care for patients WHO ave ACS or undergoing PCI according to guidelines.Itss well established that the antiplatelet response to clopidogrel varies widely among patients.Patients ...
Alev Arat Özkan
doaj   +3 more sources

Clopidogrel “resistance” [PDF]

Thrombosis and Haemostasis, 2004
Although platelets lack nuclei and are the smallest circulating human cells, they play an integral and complex role in the process of thrombosis, both physiological and pathophysiological. Activation and aggregation of platelets play a central role in the propagation of intracoronary thrombi after (1) spontaneous atherosclerotic plaque disruption that ...
Karsten, Schrör, Artur Aron, Weber, Thomas, Hohlfeld   +2 more
  +7 more sources

Comparison of Light Transmission Aggregometry and VerifyNow in Detecting Clopidogrel Resistance and Factors Affecting Clopidogrel Resistance in AMI-EST Patients Undergoing Percutaneous Coronary Intervention: A Cross-Sectional Study

Indonesian Biomedical Journal, 2021
BACKGROUND: Light transmission aggregometry (LTA) and VerifyNow is commonly used to measure platelet responsiveness to clopidogrel. This study aimed to compare the results of LTA and VerifyNow P2Y12 assay for assessing the clopidogrel resistance in ...
Astuti Giantini, Ina Susianti Timan, Erlin Listiyaningsih, Rahajuningsih Dharma, Rianto Setiabudy, Idrus Alwi, Lia Gardenia Partakusuma, Nuri Dyah Indrasari, Alida Roswita Harahap, Siskawati Suparmin, Windy Sahar, Renan Sukmawan   +11 more
doaj   +1 more source

Aspirin and Clopidogrel Resistance [PDF]

Mayo Clinic Proceedings, 2006
Despite aspirin's and clopidogrel's proven benefit in reducing cardiovascular (CV) events, recurrent CV events still occur in patients receiving antiplatelet therapy. Many of these patients are resistant or only partially responsive to the antiplatelet effects of aspirin and clopidogrel, as determined by standard platelet assays.
Erin D, Michos, Reza, Ardehali, Roger S, Blumenthal, Richard A, Lange, Hossein, Ardehali   +4 more
openaire   +4 more sources

RESISTANCE TO ANTIPLATELET DRUGS (ASPIRIN, CLOPIDOGREL) IN PATIENTS UNDERGOING ELECTIVE PERCUTANEOUS CORONARY INTERVENTION

Рациональная фармакотерапия в кардиологии, 2015
Aim. To study prevalence of resistance to acetylsalicylic acid, clopidogrel and dual resistance in percutaneous coronary intervention (PCI), to identify clinical risk factors of resistance development, to study effects of concomitant therapy on ...
V. A. Sulimov, E. V. Moroz
doaj   +3 more sources

Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease. [PDF]

PLoS ONE, 2014
Clopidogrel is an antiplatelet prodrug that is recommended to reduce the risk of recurrent thrombosis in coronary artery disease (CAD) patients. Paraoxonase 1 (PON1) is suggested to be a rate-limiting enzyme in the conversion of 2-oxo-clopidogrel to ...
Damrus Tresukosol, Bhoom Suktitipat, Saowalak Hunnangkul, Ruttakarn Kamkaew, Saiphon Poldee, Boonrat Tassaneetrithep, Atip Likidlilid   +6 more
doaj   +1 more source

Analysis of CYP2C19 gene polymorphism and influencing factors of pharmacological response of clopidogrel in patients with cerebral infarction in Zhejiang, China

Frontiers in Cardiovascular Medicine, 2023
BackgroundCertain genetic and non-genetic factors may cause damaged platelet inhibition by clopidogrel. We aimed to determine the effect of cytochrome P4502C19 (CYP2C19) polymorphism, along with other clinical factors, on the platelet response to ...
Yijun Mo, Yao Lu, Fei Guo, Aihua Wu, Yuesong Weng   +4 more
doaj   +1 more source